Drug Trial Radar · NCT03126019
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
Last checked: Nov 19, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
126
Actual
Start
Mar 14, 2018
Primary completion
Feb 26, 2021
Study completion Jun 7, 2024
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Apr 24, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the objective response rate of parsaclisib treatment in participants with relapsed or refractory follicular lymphoma.
Conditions
- Lymphoma
Interventions
ParsaclisibDrug
Parsaclisib tablets administered orally with water and without regard to food
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate With Parsaclisib Based on Lugano Classification Response CriteriaTime frame: Up to approximately 148 weeks
Locations
83 sites in 13 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates - Biltmore Cancer Center
Phoenix, Arizona
Beverly Hills Cancer Center
Beverly Hills, California
Synergy Hematology and Oncology Medical Associates
Los Angeles, California
St. Joseph Heritage Healthcare
Santa Rosa, California
American Institute of Research Corporate Office
Whittier, California
Cancer Center of Central Connecticut
Southington, Connecticut
Florida Cancer Specialists & Research Institute
Fort Myers, Florida
Asclepes Research Centers
Spring Hill, Florida
Clinical Trials of Swla Llc
Lake Charles, Louisiana
Saint Agnes Hospital
Baltimore, Maryland
Barbara Ann Karmanos Cancer Hospital
Detroit, Michigan
Hattiesburg Clinic Hematology
Hattiesburg, Mississippi
Saint Luke'S Hospital
Kansas City, Missouri
Sarah Cannon Research Institute
Kansas City, Missouri
Clinical Research Alliance, Inc.
New Hyde Park, New York
Duke University Medical Center
Durham, North Carolina
Gabrail Cancer Center
Canton, Ohio
University of Pennsylvania Health System
Philadelphia, Pennsylvania
Charleston Hematology Oncology Associates Pa
Charleston, South Carolina
Tennessee Oncology
Nashville, Tennessee
Renovatio Clinical Consultants Llc
Spring, Texas
University of Washington
Seattle, Washington
St Vincent'S Hospital Sydney
Darlinghurst, Australia
Western Health
St Albans, Victoria, Australia
Border Medical Oncology
Wodonga, Victoria, Australia
Saint John Regional Hospital
Saint John, New Brunswick, Canada
Sunnybrook Health Science Centre
Toronto, Ontario, Canada
Santa Cabrini Hospital
Montreal, Quebec, Canada
University Hospital Hradec Kralove
Hradec Králové, Czechia
Fakultni Nemocnice Ostrava
Ostrava, Czechia
University Hospital Kralovkse Vinohrady
Prague, Czechia
Univerzita Karlova V Praze 1. Lekarska Fakulta
Prague, Czechia
Fakultni Nemocnice V Motole
Prague, Czechia
Aalborg University Hospital
Aalborg, Denmark
Odense Universitetshospital (Ouh) (Odense University Hospital)
Odense C, Denmark
Bag Arnoldstr. Dresden
Dresden, Germany
University Medical Center Freiburg
Freiburg im Breisgau, Germany
Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
Mainz, Germany
University Hospital Mannheim
Mannheim, Germany
Semmelweis Egyetem
Budapest, Hungary
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.